January 27, 2022

INTRIGUE Phase III study of Qinlock fails to meet primary endpoint in gastrointestinal stromal tumor – Deciphera Pharmaceuticals

Deciphera Pharmaceuticals announced top-line results from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care. In the study, 453 patients were randomized 1:1 to either Qinlock 150 mg once daily […]

admin Health 0 50 sec read
October 8, 2021

CHMP recommends Qinlock to treat advanced gastrointestinal stromal tumor – Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. “The majority of GIST patients who […]

admin Health 0 1 min read
September 29, 2021

CHMP recommends Qinlock to treat adult patients with advanced gastrointestinal stromal tumor – Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The positive CHMP opinion is a […]

admin Health 0 1 min read

Recent Posts

Meta

Categories

Archives

Recent Comments